New inhaled drug aims to treat lung scarring with fewer side effects

NCT ID NCT06992661

Recruiting now Disease control Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 16, 2026 · Updated 4 times

Summary

This early-stage trial tests a single dose of an inhaled drug called RJ026 in 42 healthy volunteers and 42 people with interstitial lung disease (ILD). The goal is to see how much drug reaches the lungs and blood, and whether it is safe. Researchers hope that inhaling the drug will deliver higher doses to the lungs while reducing side effects seen with oral versions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RJ026 inhaled powder
What this could lead to: If successful, this could lead to a more targeted treatment for interstitial lung disease with fewer side effects than oral medication.
What could go wrong: This is a very early Phase 1 trial with only 84 participants. It primarily measures safety and drug levels, not whether the drug actually improves the disease. The drug may not work or could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis interstitial lung disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS INTERSTITIAL LUNG DISEASE (ILD)

Contacts and locations

Locations

Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine
RECRUITING

Shanghai, Shanghai Municipality, 200025, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.